vaqta 50 iu/1 ml injektionssuspension
msd belgium - hepatitis-a-virus (hav) - antigen - injektionssuspension - 50 iu/1 ml - hepatitis-a-virus (hav) - antigen - hepatitis a, inactivated, whole virus
vaqta 50 iu/1 ml injektionssuspension
msd belgium - hepatitis-a-virus (hav) - antigen - injektionssuspension - 50 iu/1 ml - hepatitis-a-virus (hav) - antigen - hepatitis a, inactivated, whole virus
vaqta junior 25 iu/0,5 ml injektionssuspension
msd belgium - hepatitis-a-virus (hav) - antigen - injektionssuspension - 25 iu/0,5 ml - hepatitis-a-virus (hav) - antigen - hepatitis a, inactivated, whole virus
vaqta junior 25 iu/0,5 ml injektionssuspension
msd belgium - hepatitis-a-virus (hav) - antigen - injektionssuspension - 25 iu/0,5 ml - hepatitis-a-virus (hav) - antigen - hepatitis a, inactivated, whole virus
havrix 1440 injektionssuspension
glaxosmithkline biologicals - hepatitis-a-virus (hav) - antigen - injektionssuspension - hepatitis-a-virus (hav) - antigen 1440 elisa u - hepatitis a, inactivated, whole virus
havrix 1440 injektionssuspension
glaxosmithkline biologicals - hepatitis-a-virus (hav) - antigen - injektionssuspension - hepatitis-a-virus (hav) - antigen 1440 elisa u - hepatitis a, inactivated, whole virus
havrix junior 720 injektionssuspension
glaxosmithkline biologicals - hepatitis-a-virus (hav) - antigen - injektionssuspension - hepatitis-a-virus (hav) - antigen 720 elisa u - hepatitis a, inactivated, whole virus
havrix junior 720 injektionssuspension
glaxosmithkline biologicals - hepatitis-a-virus (hav) - antigen - injektionssuspension - hepatitis-a-virus (hav) - antigen 720 elisa u - hepatitis a, inactivated, whole virus
heplisav b
dynavax gmbh - hepatitis-b-oberflächenantigen - hepatitis b - impfstoffe - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.
prehevbri
vbi vaccines b.v. - hepatitis-b-oberflächenantigen - hepatitis b - impfstoffe - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.